Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 59 articles: HTML format

Single Articles

March 2026
1. LEONHARDT CS, Adham M, Bazarbashi S, Ben-Aharon I, et al
   The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer.
   Lancet Oncol. 2026;27:e141-e149.
   PubMed     Abstract available
   
   
   
2. KIM Y, Bates JE, Yoon HI, Grassberger C, et al
   Cardiac radiosensitivity in the era of thoracic chemoradiotherapy and immunotherapy: a scoping review.
   Lancet Oncol. 2026;27:e130-e140.
   PubMed     Abstract available
   
   
   February 2026
3. GOURD E
   FDA fast-tracks first inhalable gene therapy for lung cancer.
   Lancet Oncol. 2026 Feb 19:S1470-2045(26)00083.
   PubMed    
   
   
   
4. CASASSUS B
   France plans national targeted lung cancer screening.
   Lancet Oncol. 2026 Feb 12:S1470-2045(26)00070.
   PubMed    
   
   
   
5. DE RUYSSCHER D, Damen PJJ, Hendriks LEL, Saw SPL, et al
   Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment.
   Lancet Oncol. 2026;27:155-158.
   PubMed    
   
   
   January 2026
6. ZHANG L, Zhang X, Wu L, Xing W, et al
   Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.
   Lancet Oncol. 2026 Jan 12:S1470-2045(25)00643.
   PubMed     Abstract available
   
   
   December 2025
7. WU YL, Yao Y, Yang JJ, Wu L, et al
   Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study.
   Lancet Oncol. 2025 Dec 6:S1470-2045(25)00594.
   PubMed     Abstract available
   
   
   
8. DOUMA LH, van der Noort V, Lalezari F, de Vries JF, et al
   Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.
   Lancet Oncol. 2025;26:1676-1684.
   PubMed     Abstract available
   
   
   November 2025
9. ROBBINS HA, Johansson M
   Defining eligibility for lung cancer screening based on individual risk.
   Lancet Oncol. 2025 Nov 10:S1470-2045(25)00537.
   PubMed    
   
   
   
10. VOGEL-CLAUSSEN J, Bollmann BA, May K, Stiebeler S, et al
    Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study.
    Lancet Oncol. 2025 Nov 10:S1470-2045(25)00490.
    PubMed     Abstract available
    
    
    
11. FUEREDER T, Garde-Noguera J, Garcia-Mosquera JJ, Ruiz-Borrego M, et al
    Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2025;26:1454-1466.
    PubMed     Abstract available
    
    
    October 2025
12. NADAL E, Navarro-Martin A
    Radiotherapy-free approach in inoperable locally advanced non-small-cell lung cancer: are we ready for this shift?
    Lancet Oncol. 2025 Oct 10:S1470-2045(25)00485.
    PubMed    
    
    
    
13. HATA A, Ninomaru T, Okada H, Kogure Y, et al
    Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.
    Lancet Oncol. 2025 Oct 10:S1470-2045(25)00462.
    PubMed     Abstract available
    
    
    
14. DI FEDERICO A, Wang K, Chen MF, Barsouk AA, et al
    First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF(V600E)-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
    Lancet Oncol. 2025;26:1357-1369.
    PubMed     Abstract available
    
    
    September 2025
15. DI FEDERICO A, Stumpo S, Mantuano F, De Giglio A, et al
    Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis.
    Lancet Oncol. 2025 Sep 29:S1470-2045(25)00429.
    PubMed     Abstract available
    
    
    
16. COLLINGRIDGE D
    2025 World Conference on Lung Cancer.
    Lancet Oncol. 2025 Sep 11:S1470-2045(25)00548.
    PubMed    
    
    
    
17. PAULSON KG, Lau SCM, Ahn MJ, Moskovitz M, et al
    Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.
    Lancet Oncol. 2025 Sep 8:S1470-2045(25)00480.
    PubMed     Abstract available
    
    
    June 2025
18. ZHOU C, Wang Z, Sun M, Cao L, et al
    Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.
    Lancet Oncol. 2025 Jun 13:S1470-2045(25)00198.
    PubMed     Abstract available
    
    
    March 2025
19. BHAMANI A, Creamer A, Verghese P, Prendecki R, et al
    Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study.
    Lancet Oncol. 2025 Mar 25:S1470-2045(25)00082.
    PubMed     Abstract available
    
    
    
20. HEUVELMANS MA
    Lung cancer screening implementation: turning evidence into practice.
    Lancet Oncol. 2025 Mar 25:S1470-2045(25)00138.
    PubMed    
    
    
    
21. GOURD E
    Lung cancer treatment compromised by delayed genomic test results.
    Lancet Oncol. 2025 Mar 13:S1470-2045(25)00149.
    PubMed    
    
    
    February 2025
22. LI Z, Wang Y, Sun Y, Wang L, et al
    Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study.
    Lancet Oncol. 2025 Feb 25:S1470-2045(25)00012.
    PubMed     Abstract available
    
    
    January 2025
23. SEN T, Dotsu Y, Corbett V, Puri S, et al
    Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies.
    Lancet Oncol. 2025;26:e13-e33.
    PubMed     Abstract available
    
    
    
24. XU Y, Chen K, Xu Y, Li H, et al
    Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2025;26:74-84.
    PubMed     Abstract available
    
    
    December 2024
25. ZHAO Y, Xiong S, Ren Q, Wang J, et al
    Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study.
    Lancet Oncol. 2024 Dec 6:S1470-2045(24)00599.
    PubMed     Abstract available
    
    
    November 2024
26. GOURD E
    Lung cancer rates highest among British Bangladeshi men.
    Lancet Oncol. 2024 Nov 28:S1470-2045(24)00683.
    PubMed    
    
    
    
27. HEINZERLING JH, Mileham KF, Robinson MM, Symanowski JT, et al
    Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2024 Nov 27:S1470-2045(24)00573.
    PubMed     Abstract available
    
    
    
28. FURLOW B
    American Lung Association calls for expanded insurance coverage for lung cancer screening.
    Lancet Oncol. 2024 Nov 21:S1470-2045(24)00670.
    PubMed    
    
    
    
29. THUREAU S, Giraud P, Zalcman G, Vera P, et al
    [(18)F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2024;25:e541.
    PubMed    
    
    
    
30. BOWEN JONES S, Cooke S, Belderbos J, Faivre-Finn C, et al
    [(18)F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer.
    Lancet Oncol. 2024;25:e540.
    PubMed    
    
    
    
31. XU X, Ye L, Shi J, Li H, et al
    [(18)F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer.
    Lancet Oncol. 2024;25:e539.
    PubMed    
    
    
    October 2024
32. PROVENCIO M, Nadal E, Insa A, Garcia Campelo R, et al
    Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2024 Oct 14:S1470-2045(24)00498.
    PubMed     Abstract available
    
    
    
33. WOLF J, Hochmair M, Han JY, Reguart N, et al
    Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
    Lancet Oncol. 2024;25:1357-1370.
    PubMed     Abstract available
    
    
    August 2024
34. GOURD E
    World's first lung cancer vaccine trial launched in the UK.
    Lancet Oncol. 2024 Aug 30:S1470-2045(24)00324.
    PubMed    
    
    
    
35. ZHAO Y, He Y, Wang W, Cai Q, et al
    Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.
    Lancet Oncol. 2024 Aug 16:S1470-2045(24)00379.
    PubMed     Abstract available
    
    
    
36. VERA P, Thureau S, Le Tinier F, Chaumet-Riffaud P, et al
    Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [(18)F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 t
    Lancet Oncol. 2024 Aug 9:S1470-2045(24)00320.
    PubMed     Abstract available
    
    
    
37. WU YL, Guarneri V, Voon PJ, Lim BK, et al
    Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
    Lancet Oncol. 2024;25:989-1002.
    PubMed     Abstract available
    
    
    
38. TENDLER S, Dunphy MP, Agee M, O'Donoghue J, et al
    Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
    Lancet Oncol. 2024;25:1015-1024.
    PubMed     Abstract available
    
    
    July 2024
39. LAZARATOS AM, Petrecca K, Guiot MC, Jerzak KJ, et al
    CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer.
    Lancet Oncol. 2024;25:e282.
    PubMed    
    
    
    
40. AERTS JG, Belderbos R, Baas P, Scherpereel A, et al
    Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase
    Lancet Oncol. 2024;25:865-878.
    PubMed     Abstract available
    
    
    
41. ZAUDERER MG, Dagogo-Jack I
    Refreshing the mesothelioma catalogue: tailoring cellular therapy in the DENIM trial.
    Lancet Oncol. 2024;25:825-827.
    PubMed    
    
    
    June 2024
42. CHEN L, Zhu XZ, Zhao SJ, Yang QW, et al
    PD-L1 as a predictive factor for non-small-cell lung cancer prognosis.
    Lancet Oncol. 2024;25:e233.
    PubMed    
    
    
    May 2024
43. BURKI T
    EPA ruling to ban chrysotile asbestos.
    Lancet Oncol. 2024;25:537.
    PubMed    
    
    
    April 2024
44. SMIT EF, Felip E, Uprety D, Nagasaka M, et al
    Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
    Lancet Oncol. 2024;25:439-454.
    PubMed     Abstract available
    
    
    March 2024
45. GOULART BHL, Mushti SL, Chatterjee S, Larkins E, et al
    Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis.
    Lancet Oncol. 2024 Mar 5:S1470-2045(24)00040.
    PubMed     Abstract available
    
    
    February 2024
46. RHA SY, Bordia S
    Pembrolizumab plus chemotherapy for advanced gastric cancer - Authors' reply.
    Lancet Oncol. 2024;25:e52.
    PubMed    
    
    
    
47. SCHUTTE T, Derks S, van Laarhoven HWM
    Pembrolizumab plus chemotherapy for advanced gastric cancer.
    Lancet Oncol. 2024;25:e51.
    PubMed    
    
    
    
48. HUANG CY, Wu XB
    Pembrolizumab plus chemotherapy for advanced gastric cancer.
    Lancet Oncol. 2024;25:e50.
    PubMed    
    
    
    January 2024
49. RASHID T, Bennett JE, Muller DC, Cross AJ, et al
    Mortality from leading cancers in districts of England from 2002 to 2019: a population-based, spatiotemporal study.
    Lancet Oncol. 2024;25:86-98.
    PubMed     Abstract available
    
    
    December 2023
50. LEAL T, Langer C
    Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2023;24:e454.
    PubMed    
    
    
    
51. OLIVIER T, Addeo A
    Tumor Treating Fields therapy in metastatic non-small-cell lung cancer.
    Lancet Oncol. 2023;24:e453.
    PubMed    
    
    
    
52. FURLOW B
    IASLC calls for clinical trials to use tobacco use data.
    Lancet Oncol. 2023;24:1309.
    PubMed    
    
    
    November 2023
53. SCOTT SE, Gildea C, Nicholson BD, Evans RE, et al
    Future cancer risk after urgent suspected cancer referral in England when cancer is not found: a national cohort study.
    Lancet Oncol. 2023;24:1242-1251.
    PubMed     Abstract available
    
    
    
54. DOUMA LH, Lalezari F, van der Noort V, de Vries JF, et al
    Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
    Lancet Oncol. 2023;24:1219-1228.
    PubMed     Abstract available
    
    
    October 2023
55. COOPER WA
    Lessons and opportunities from improved understanding of global lung cancer histological subtypes.
    Lancet Oncol. 2023 Oct 11:S1470-2045(23)00475.
    PubMed    
    
    
    
56. ZHANG Y, Vaccarella S, Morgan E, Li M, et al
    Global variations in lung cancer incidence by histological subtype in 2020: a population-based study.
    Lancet Oncol. 2023 Oct 11:S1470-2045(23)00444.
    PubMed     Abstract available
    
    
    
57. HU X, Wang C, Huang W, Barber SM, et al
    Pembrolizumab monotherapy for advanced chordoma.
    Lancet Oncol. 2023;24:e399.
    PubMed    
    
    
    September 2023
58. FENNELL DA
    Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer.
    Lancet Oncol. 2023;24:946-947.
    PubMed    
    
    
    
59. LEAL T, Kotecha R, Ramlau R, Zhang L, et al
    Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 st
    Lancet Oncol. 2023;24:1002-1017.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum